Dublin, May 20, 2025 (GLOBE NEWSWIRE) -- The "U.S. Small Molecule Innovator API CDMO Market Size, Share & Trends Analysis Report by Stage Type (Preclinical, Clinical, Commercial), Service, Customer Type, Therapeutic Area, Region, with Growth Forecasts, 2025-2030" report has been added to ResearchAndMarkets.com's offering.
The U.S. Small Molecule Innovator API CDMO Market was valued at USD 8.8 Billion in 2024, and is projected to reach USD 12.6 Billion by 2030, rising at a CAGR of 6%. A growing outsourcing trend among pharmaceutical companies, increasing demand for small molecule drugs, and surge in clinical trials are anticipated to influence the U.S. market positively.
Small molecules continue to play an important role in developing new treatments globally. Specialty medicines are increasingly driving U.S. pharmaceutical growth, particularly in developed markets, with small molecule applications accounting for over half of specialty sales. In addition, enhanced efficiency serves as another pivotal driver for pharmaceutical outsourcing. With mounting pressure on pharmaceutical companies to expedite the introduction of new drugs to the market, outsourcing emerges as a solution to accelerate the drug development process. Leveraging their expertise, experience, and cutting-edge equipment, CDMOs facilitate the swift & efficient production of high-quality drugs, enabling pharmaceutical firms to adhere to their development schedules.
The pharmaceutical/biotechnology companies increasingly opt for CDMO services to leverage their expertise. CDMOs offer flexibility & scalability in manufacturing capacity, allowing pharmaceutical companies to adapt to changing market demands and accelerate time to market for new therapies. In addition to providing extended expertise and assisting in improved cash flow management, outsourcing brings significant manufacturing advantages, including reducing investment risks. In the context of early-stage technologies and products, establishing expensive in-house capabilities entails substantial risks across the product development phases. At the same time, outsourcing serves as a risk-averse alternative.
The preference for outsourcing small molecule API has grown as an effective strategy until market demand for products becomes well-established and understood. For instance, in May 2022, Piramal Pharma Limited's Pharma Solutions business, a CDMO, inaugurated a new API facility at its site in Aurora, Ontario. This state-of-the-art plant has commenced operations & has completed its initial production runs.
U.S. Small Molecule Innovator API CDMO Market Report Highlights
- Based on stage, the clinical segment led the market with the largest revenue share of 54.68% in 2024. The segment growth can be attributed to the rising clinical trial (Phase I-III) activities, growing small molecule development pipeline, and increasing availability of expertise
- Based on the customer type, the pharmaceutical segment held the market with the largest revenue share in 2024, attributing to rising funding for drug development is propelling segment growth
- Based on therapeutic area, the oncology segment accounted for the largest revenue share in 2024. The segment is driven by increasing prevalence of cancer in U.S. In addition, high R&D investments in advanced therapeutics to minimize cancer disease burden are expected to boost segment growth
- West Group dominated the U.S. market with the largest revenue share of 33.07% in 2024. The presence of various factors, such as increasing prevalence of chronic diseases, demand for APIs & CDMO services and improving healthcare infrastructure is expected to drive market significantly
Why Should You Buy This Report?
- Comprehensive Market Analysis: Gain detailed insights into the market across major regions and segments.
- Competitive Landscape: Explore the market presence of key players.
- Future Trends: Discover the pivotal trends and drivers shaping the future of the market.
- Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.
This report addresses:
- Market intelligence to enable effective decision-making
- Market estimates and forecasts from 2018 to 2030
- Growth opportunities and trend analyses
- Segment and regional revenue forecasts for market assessment
- Competition strategy and market share analysis
- Product innovation listings for you to stay ahead of the curve
Key Attributes
| Report Attribute | Details |
| No. of Pages | 120 |
| Forecast Period | 2024-2030 |
| Estimated Market Value (USD) in 2024 | $8.8 Billion |
| Forecasted Market Value (USD) by 2030 | $12.6 Billion |
| Compound Annual Growth Rate | 6% |
| Regions Covered | United States |
The companies profiled in this U.S. Small Molecule Innovator API CDMO market report include:
- Lonza
- Novo Holdings (Catalent, Inc.)
- Thermo Fisher Scientific, Inc.
- Siegfried Holding AG
- Recipharm AB
- CordenPharma International
- Samsung Biologics
- Labcorp
- Ajinomoto Bio-Pharma Services
- Piramal Pharma Solutions
- Jubilant Life Sciences (Jubilant Biosys Limited)
For more information about this report visit https://www.researchandmarkets.com/r/cbc6hm
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
